Document is current
Any future updates will be listed below
-
Authors
Mohl, Gregory A.
Dixon, Gary
Marzette, Emily
McKetney, Justin
Samelson, Avi J.
Serras, Carlota Pereda
Jin, Julianne
Ariqat, Nabeela
Keys, Andrea
Chavira, Cristian
Li, Andrew
Boggess, Steven C.
Swaney, Danielle L.
Kampmann, Martin
-
Funding
Funding for this research was provided by:
A.P. Gianni Foundation (Postdoctoral Fellowship)
National Institute for neurological disorders and stroke (U54 NS123746)
National Institute for neurological disorders and stroke (U54 NS123746)
National Institute for neurological disorders and stroke (U54 NS100717)
National Institute on Aging (F32 AG063487)
National Institute on Aging (R01 AG062359)
Alzheimer’s Association (23AARF-1027616)
Rainwater Charitable Foundation (Tau Consortium Award)
Chan Zuckerberg Initiative (Ben Barres Early Career Acceleration Award)
- License Information
-
More Information
Article History
Received: 24 August 2025
Accepted: 6 March 2026
First Online: 25 April 2026
Competing interests
: M.K. is a co-scientific founder of Montara Therapeutics and serves on the Scientific Advisory Boards of Engine Biosciences, Casma Therapeutics, Alector, and Montara Therapeutics, and is an advisor to Modulo Bio and Theseus Therapies. M.K. is an inventor on US Patent 11,254,933 related to CRISPRi and CRISPRa screening, and on a US Patent application on in vivo screening methods.
